Literature DB >> 9766674

Insulin-like growth factor II and PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma.

W Wang1, P Kumar, W Wang1, J Epstein, L Helman, J V Moore, S Kumar.   

Abstract

The mouse myoblast C2C12 cell line transfected singly with cDNA for Pax-3, PAX3-FKHR, or insulin-like growth factor (IGF) II or cotransfected with IGF-II plus Pax-3 or with IGF-II plus PAX3-FKHR genes showed an altered morphology, a lack of differentiation, and higher proliferation rates in vitro. On s.c. injection into nude mice, tumors grew from transfected cell lines but not from cells transfected with the empty vector. Tumors derived from IGF-II/PAX3-FKHR- and IGF-II-transfected cells grew most rapidly. Cotransfection of IGF-II plus Pax-3 induced tumors comprised highly differentiated striated muscle cells; Pax-3, PAX3-FKHR, or IGF-II transfection produced tumors at varying stages of differentiation. Tumors derived from IGF-II plus PAX3-FKHR-cotransfected cells were composed of undifferentiated cells. This was the only tumor type to infiltrate the underlying muscle. The most angiogenesis and the least apoptosis were observed in the latter tumors. These results support the hypothesis that PAX3-FKHR interacts with IGF-II to play a critical role in the oncogenesis of rhabdomyosarcoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9766674

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.

Authors:  E Anders Kolb; Richard Gorlick; John M Maris; Stephen T Keir; Christopher L Morton; Jianrong Wu; Amy W Wozniak; Malcolm A Smith; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2011-05-31       Impact factor: 3.167

2.  The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase.

Authors:  Matthew J Martin; Nataliya Melnyk; Michelle Pollard; Mary Bowden; Hon Leong; Thomas J Podor; Martin Gleave; Poul H B Sorensen
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

3.  Comparative analysis of paired- and homeodomain-specific roles in PAX3-FKHR oncogenesis.

Authors:  Youbin Zhang; Joel Schwartz; Chiayeng Wang
Journal:  Int J Clin Exp Pathol       Date:  2008-12-01

4.  Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation.

Authors:  Susanne V Allander; Peter B Illei; Yidong Chen; Cristina R Antonescu; Mike Bittner; Marc Ladanyi; Paul S Meltzer
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

5.  Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells.

Authors:  F Frasca; G Pandini; P Scalia; L Sciacca; R Mineo; A Costantino; I D Goldfine; A Belfiore; R Vigneri
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

6.  cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene.

Authors:  J Khan; M L Bittner; L H Saal; U Teichmann; D O Azorsa; G C Gooden; W J Pavan; J M Trent; P S Meltzer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

7.  PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma.

Authors:  J Anderson; A Ramsay; S Gould; K Pritchard-Jones
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

8.  The over-expression of cell migratory genes in alveolar rhabdomyosarcoma could contribute to metastatic spread.

Authors:  Elizabeth Rapa; Sophie K Hill; Karl J Morten; Michelle Potter; Chris Mitchell
Journal:  Clin Exp Metastasis       Date:  2012-03-14       Impact factor: 5.150

9.  Insulin-like growth factor 1 receptor stabilizes the ETV6-NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation.

Authors:  Cristina E Tognon; Bo Rafn; Naniye Malli Cetinbas; Takumi Kamura; Genny Trigo; Barak Rotblat; Fumihiko Okumura; Masaki Matsumoto; Christine Chow; Monika Davare; Michael Pollak; Thibault Mayor; Poul H Sorensen
Journal:  J Biol Chem       Date:  2018-06-14       Impact factor: 5.157

Review 10.  Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials.

Authors:  Margaret E Macy; Kelly K Sawczyn; Timothy P Garrington; Douglas K Graham; Lia Gore
Journal:  Curr Oncol Rep       Date:  2008-11       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.